- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07487194
Base de données mondiale d'utilisation et de registre pour l'amélioration de la préservation du pancréas de donneur (GUARDIAN-PANCREAS)
Base de données mondiale d'utilisation et de registre pour l'amélioration de la préservation des pancréas de donneurs (GUARDIAN-PANCREAS)
The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving pancreas transplants using donor pancreata transported via the PancreasPak system. These results will be compared to standard of care outcomes, as well as other preservation methods.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
GUARDIAN-PANCREAS is a post-market, observational registry of adult transplant recipient patients whose donor pancreas was preserved and transported within the PancreasPak. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.
About 1000 subjects meeting the study inclusion and exclusion criteria will be enrolled into the study at about 15 clinical sites.
Candidates that fit the eligibility criteria and have had their donor pancreas transported with a Paragonix product or a standard of care method can be enrolled. The baseline characteristics and outcomes of the two groups will be compared.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Amanda Schreiner
- Numéro de téléphone: 22 781-428-4153
- E-mail: aschreiner@paragonixtechnologies.com
Sauvegarde des contacts de l'étude
- Nom: Julia Hersum
- Numéro de téléphone: 4 781-428-4153
- E-mail: julia@paragonixtechnologies.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients who have received a pancreas transplant at centers that use the PancreasPak device.
La description
Inclusion Criteria:
• Adult or pediatric recipients of pancreas alone, simultaneous pancreas-kidney, or pancreas after kidney transplant
Exclusion Criteria:
- Donor pancreata that do not meet institutional clinical requirements for transplantation
- Simultaneous pancreas-kidney transplant recipients who received donor organs from multiple donors
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: RETROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
PancreasPak patient
Patients whose donor pancreas was transported with the PancreasPak device. |
The PancreasPak Donor Preservation System is a FDA cleared and CE-marked medical device intended to be used for the static hypothermic preservation of donor pancreata during transportation and eventual transplantation using cold preservation solutions indicated for use in donor pancreata transplantation. The intended organ preservation time for the PancreasPak system is up to 21 hours. |
|
Standard method patients
Patients whose donor pancreas was transported with a method other than the PancreasPak device. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Graft dysfunction
Délai: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who experience graft dysfunction post-transplant. |
Post-transplant through 1 year post-transplant
|
|
Pancreatitis
Délai: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who experience pancreatitis post-transplant. |
Post-transplant through 1 year post-transplant
|
|
Primary Non-Function
Délai: Post-transplant through 7 days post-transplant
|
The percentage of subjects in each cohort who primary non-function post transplantation. |
Post-transplant through 7 days post-transplant
|
|
Length of Hospital Stay
Délai: 1 year
|
How many days the patients stays in the hospital post-transplant. |
1 year
|
|
Surgical Complications
Délai: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who experience surgical complications. |
Post-transplant through 1 year post-transplant
|
|
Insulin Dependence
Délai: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who experience insulin dependence post-transplant. |
Post-transplant through 1 year post-transplant
|
|
Graft Failure
Délai: Post-transplant through 1 year post
|
The percentage of subjects in each cohort who develop graft failure post-transplant. |
Post-transplant through 1 year post
|
|
Survival
Délai: Post-transplant through 1 year post
|
The percentage of subjects in each cohort who survive through 1 year post-transplant. |
Post-transplant through 1 year post
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Length of ICU Stay
Délai: 1 year
|
How many days the patient stayed in the ICU post-transplant. |
1 year
|
|
Interventions for Anastomotic Complications
Délai: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who required interventions due to anastomotic complications. |
Post-transplant through 1 year post-transplant
|
|
Intervention for Vascular Complications
Délai: Post-transplant through 1 year-post transplant
|
The percentage of subjects in each cohort who required interventions due to vascular complications. |
Post-transplant through 1 year-post transplant
|
|
Medications
Délai: Post-transplant through 1 year post-transplant
|
The percentage of subjects in each cohort who required the use of various medications. |
Post-transplant through 1 year post-transplant
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PGX-008
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .